Welcome to our dedicated page for Redhill Biopharm SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RedHill Biopharma Ltd. files foreign-issuer reports that document its specialty biopharmaceutical business, ADS capital structure and corporate governance. Recent Form 6-K reports incorporate press releases and meeting materials covering Talicia commercialization, RHB-204, RHB-102 and opaganib development disclosures, and clinical or regulatory updates tied to gastrointestinal, infectious-disease and oncology programs.
The company’s SEC record also includes shareholder-meeting notices and voting results for restricted share unit grants and authorized share-capital changes, as well as Nasdaq listing-compliance communications for its American depositary shares. Incorporation-by-reference language links these current reports to Form S-8 equity compensation registrations and Form F-3 shelf registration statements, reflecting recurring disclosure topics around financing capacity, equity plans, governance and material events.
RedHill Biopharma Ltd. Chief Operating Officer Gilead Raday reported compensation-related share activity tied to restricted share unit vesting. A trustee sold 1,574 American Depositary Shares (ADS) solely to cover tax withholding, at $0.8001 per ADS, equal to 15,740,000 ordinary shares based on 10,000 ordinary shares per ADS. Following this sale, Raday’s direct holdings in ordinary shares were 261,060,000. He also exercised derivative rights over 30,780,000 ADS representing 30,780,000 underlying ordinary shares, leaving 76,150,000 ADS directly held. Footnotes state the transaction was executed under a sell-to-cover policy and did not represent a discretionary trade by Raday.
RedHill Biopharma reports new preclinical data on its investigational drug opaganib, presented in two posters at the 2026 American Association for Cancer Research meeting. In neuroblastoma models, opaganib appeared to enhance the effect of an oxaliplatin plus doxorubicin chemotherapy combination by destabilizing n-Myc and increasing cancer cell apoptosis.
In triple-negative breast cancer cell models, pretreatment with opaganib followed by low-dose diABZI potentiated STING-mediated signaling, suggesting a possible boost to anti-tumor immunity. Opaganib has FDA Orphan Drug and Rare Pediatric Disease designations for neuroblastoma and is already in a Bayer-supported Phase 2 study in metastatic castrate-resistant prostate cancer.
RedHill Biopharma Ltd. reported receiving a notice from Nasdaq that its American Depositary Shares have failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, from February 20, 2026 to April 2, 2026.
Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days, until October 5, 2026, to regain compliance by having its ADS bid price close at or above $1.00 for at least 10 consecutive business days. RedHill’s ADSs remain listed on the Nasdaq Capital Market, and the company states that its operations are not affected by this notice at this time.
RedHill Biopharma Ltd. director Tsimchi Ofer filed an initial Form 3 reporting his equity holdings in the company. The filing shows direct ownership of 146,250,000 Ordinary Shares and 3,644 American Depositary Shares (ADSs), which are convertible into Ordinary Shares at the holder’s election with no expiration date.
Ofer also reports 14,625 unvested restricted share units, each linked to one ADS and settled in Ordinary Shares. In addition, he holds stock options over 150,000, 90,000 and 180,000 Ordinary Shares, with exercise prices of $5,000, $4,870 and $7,080 per ADS, expiring on May 6, 2029, March 25, 2030 and April 28, 2031, respectively.
RedHill Biopharma Ltd. director and Chief Commercial Officer Rick D. Scruggs filed an initial Form 3 disclosing his holdings in the company. As of the filing, he directly owns 312,500,000 Ordinary Shares, along with American Depositary Shares (ADSs) and equity awards linked to additional Ordinary Shares.
His equity-based compensation includes 31,250 unvested restricted share units, each tied to one ADS and settled in Ordinary Shares, plus 7,364 ADSs that are convertible at any time with no expiration date. He also holds fully vested stock options covering 750,000, 300,000, 70,000 and 840,000 Ordinary Shares, each granted under the RedHill 2010 Option Plan with exercise prices per ADS of $6,840, $7,000, $7,000 and $6,620, expiring between February 25, 2029 and July 25, 2031.
RedHill Biopharma Ltd. director Reed Kenneth filed an initial ownership report showing equity interests in the company. He holds 10,520 unvested restricted share units, each tied to one American Depositary Share and settled in ordinary shares, plus 2,583 ADSs that are convertible at any time and have no expiration date.
He also holds stock options to purchase 90,000 ordinary shares (equivalent to 9 ADSs) at an exercise price of $4,870 per ADS expiring on March 25, 2030, 150,000 ordinary shares (equivalent to 15 ADSs) at $7,000 per ADS expiring on May 6, 2029, and 250,000 ordinary shares (equivalent to 25 ADSs) at $6,620 per ADS expiring on July 25, 2031. These options are fully vested and exercisable.
RedHill Biopharma’s Chief Operating Officer Raday Gilead has filed an initial Form 3 reporting his equity holdings. He holds 30,758 unvested restricted share units, each linked to one American Depositary Share (ADS), and 4,537 ADSs that are convertible at any time with no expiration date.
The filing also lists several stock option grants to purchase Ordinary Shares: 250,000 and 400,000 shares with an exercise price of $5,000 per ADS, 600,000 shares at $4,870 per ADS, and 570,000 and 180,000 shares at $7,080 per ADS. Most option grants are described as fully vested and exercisable, with expirations between March 2028 and April 2031.
RedHill Biopharma Ltd. director Mamluk Roni has filed an initial ownership report detailing existing equity awards and share holdings. The filing shows 10,350 unvested restricted share units, each tied to one American Depositary Share (ADS). Each ADS represents 10,000 ordinary shares of RedHill Biopharma Ltd.
The RSUs are subject to time-based vesting conditions and are settled in ordinary shares. The report also discloses 1,350 ADSs that are convertible at any time at the holder’s election and have no expiration date. This Form 3 does not reflect new buy or sell transactions, only current beneficial ownership.
RedHill Biopharma Ltd. Chief Financial Officer Ingber Razi filed a Form 3 reporting existing equity interests in the company, rather than new open‑market trades. The filing lists American Depositary Shares (ADSs), restricted share units (RSUs) and stock options tied to Ordinary Shares.
The holdings include 27,756 unvested RSUs, each for one ADS, with each ADS representing 10,000 Ordinary Shares of par value NIS 0.01. The filing also notes 6,691 ADSs that are convertible at any time with no expiration date, plus fully vested stock options to purchase 20,000, 30,000, 170,000 and 230,000 Ordinary Shares at fixed exercise prices per ADS, expiring between August 29, 2028 and April 28, 2031.
RedHill Biopharma Ltd. executive Guy Joel Goldberg filed a Form 3 reporting his initial ownership in the company. He directly holds American Depositary Shares and Ordinary Shares, including 30,572 unvested restricted share units, each tied to one ADS that represents 10,000 Ordinary Shares. He also holds fully vested stock options to purchase 250,000, 450,000, 370,000 and 600,000 Ordinary Shares at exercise prices of $5,000, $4,870, $5,000 and $7,080 per ADS, expiring between 2028 and 2031.